MEDISTIM ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 181 NOK | +3.43% |
|
+2.84% | -15.42% |
| Apr. 25 | Transcript : Medistim ASA, Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 24 | Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,492 | 4,550 | 6,693 | 4,216 | 3,912 | 3,205 | - | - |
| Enterprise Value (EV) 1 | 3,462 | 4,508 | 6,581 | 4,216 | 3,866 | 3,127 | 3,086 | 3,043 |
| P/E ratio | 49.7 x | 65.8 x | 73.8 x | 37 x | 37.7 x | 29.8 x | 27.1 x | 25.7 x |
| Yield | 1.43% | 1.2% | 1.02% | - | 2.1% | 2.57% | 1.93% | 2.11% |
| Capitalization / Revenue | 9.6 x | 12.5 x | 15.7 x | 8.57 x | 7.43 x | 5.95 x | 5.69 x | 5.39 x |
| EV / Revenue | 9.52 x | 12.4 x | 15.4 x | 8.57 x | 7.34 x | 5.81 x | 5.48 x | 5.12 x |
| EV / EBITDA | 32.1 x | 38 x | 47.1 x | 25.6 x | 24.9 x | 18.8 x | 17.1 x | 16.1 x |
| EV / FCF | 51.9 x | 70.8 x | 56.4 x | - | 46.3 x | 44.7 x | 28.6 x | - |
| FCF Yield | 1.93% | 1.41% | 1.77% | - | 2.16% | 2.24% | 3.5% | - |
| Price to Book | 14.7 x | 17.7 x | 21.9 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 18,189 | 18,201 | 18,213 | 18,252 | 18,279 | 18,314 | - | - |
| Reference price 2 | 192.0 | 250.0 | 367.5 | 231.0 | 214.0 | 175.0 | 175.0 | 175.0 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 3/1/23 | 2/29/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 363.7 | 363.1 | 427.3 | 491.9 | 526.4 | 538.5 | 563.2 | 594.9 |
| EBITDA 1 | 107.8 | 118.6 | 139.7 | 164.5 | 155.1 | 166.6 | 180.2 | 189 |
| EBIT 1 | 89.77 | 95.48 | 116.3 | 141.3 | 131.4 | 147.4 | 164.1 | 173 |
| Operating Margin | 24.68% | 26.29% | 27.21% | 28.71% | 24.97% | 27.38% | 29.14% | 29.08% |
| Earnings before Tax (EBT) 1 | 91.04 | 91.61 | 114.1 | 146 | 135.2 | 145.3 | 163.1 | 172 |
| Net income 1 | 70.31 | 69.39 | 90.9 | 114 | 103.8 | 107.3 | 118.1 | 125 |
| Net margin | 19.33% | 19.11% | 21.27% | 23.17% | 19.72% | 19.93% | 20.97% | 21.01% |
| EPS 2 | 3.860 | 3.800 | 4.980 | 6.240 | 5.670 | 5.869 | 6.456 | 6.820 |
| Free Cash Flow 1 | 66.7 | 63.66 | 116.7 | - | 83.46 | 70 | 108 | - |
| FCF margin | 18.34% | 17.53% | 27.3% | - | 15.86% | 13% | 19.18% | - |
| FCF Conversion (EBITDA) | 61.88% | 53.67% | 83.5% | - | 53.81% | 42.02% | 59.93% | - |
| FCF Conversion (Net income) | 94.87% | 91.75% | 128.33% | - | 80.39% | 65.21% | 91.47% | - |
| Dividend per Share 2 | 2.750 | 3.000 | 3.750 | - | 4.500 | 4.500 | 3.377 | 3.690 |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 3/1/23 | 2/29/24 | - | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 102.1 | 112.7 | 116.1 | 117.5 | 116.5 | 141.8 | 129.3 | 137.4 | 124.1 | 135.6 | 133.8 | 135 | 134 | 136 | 138 |
| EBITDA 1 | 30.99 | 25.49 | 39.29 | 43.14 | 39.7 | 42.41 | 39.23 | 47.72 | 38.85 | 29.3 | 38.41 | 42 | 43 | 43 | 44 |
| EBIT 1 | 25.08 | 19.46 | 33.42 | 37.34 | 34.02 | 36.47 | 33.45 | 42.22 | 33.52 | 22.26 | 32.07 | 37 | 39 | 39 | 40 |
| Operating Margin | 24.55% | 17.26% | 28.78% | 31.78% | 29.2% | 25.72% | 25.88% | 30.73% | 27.01% | 16.41% | 23.97% | 27.41% | 29.1% | 28.68% | 28.99% |
| Earnings before Tax (EBT) 1 | 23.98 | 19.42 | 32.89 | 40.73 | 30.52 | 41.91 | 34.2 | 41.03 | 33.59 | 26.39 | 30.66 | 37 | 38 | 39 | 40 |
| Net income 1 | 18.8 | 16.11 | 23.72 | 33.12 | 24.65 | 32.48 | 25.67 | 32.92 | 26.13 | 19.11 | 24.38 | 27 | 28 | 28 | 29 |
| Net margin | 18.4% | 14.29% | 20.43% | 28.19% | 21.16% | 22.9% | 19.86% | 23.96% | 21.06% | 14.09% | 18.22% | 20% | 20.9% | 20.59% | 21.01% |
| EPS 2 | 1.030 | 0.8800 | 1.300 | 1.810 | 1.350 | 1.780 | 1.410 | 1.800 | 1.430 | 1.040 | 1.330 | 1.470 | 1.520 | 1.550 | 1.580 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/22/21 | 2/25/22 | 4/28/22 | 8/23/22 | 10/28/22 | 3/1/23 | 4/25/23 | 8/31/23 | 10/27/23 | 2/29/24 | 4/25/24 | - | - | - | - |
1NOK in Million2NOK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 30.4 | 42.7 | 112 | - | 46.1 | 78 | 119 | 162 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 66.7 | 63.7 | 117 | - | 83.5 | 70 | 108 | - |
| ROE (net income / shareholders' equity) | 31.7% | 28.1% | 32.3% | - | 27.1% | 27.2% | 28.2% | - |
| ROA (Net income/ Total Assets) | 23.2% | 20.4% | 30.2% | - | - | 21.9% | 23.3% | - |
| Assets 1 | 302.8 | 341 | 301.3 | - | - | 490.1 | 506.8 | - |
| Book Value Per Share | 13.00 | 14.10 | 16.80 | - | - | - | - | - |
| Cash Flow per Share | - | 4.080 | 7.030 | - | - | - | - | - |
| Capex 1 | 13.7 | 10.6 | 11.5 | - | 29.7 | 14 | 14 | 15 |
| Capex / Sales | 3.76% | 2.93% | 2.69% | - | 5.65% | 2.6% | 2.49% | 2.52% |
| Announcement Date | 2/28/20 | 2/26/21 | 2/25/22 | 3/1/23 | 2/29/24 | - | - | - |
1NOK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
175
NOK
Average target price
190
NOK
Spread / Average Target
+8.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.42% | 290M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +2.13% | 63.06B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B |
- Stock Market
- Equities
- MEDI Stock
- Financials Medistim ASA
